CMS Extends and Narrows Nationwide Temporary Moratorium on Enrollment of New Medicare Hospices
On November 16, 2026, CMS published a notice announcing its extension and modification of the nationwide temporary moratorium on the enrollment of new Medicare hospices, effective November 12, 2026, for an additional six months. CMS cites the continuing significant potential for fraud, waste, and abuse as the basis for continuing the moratorium.
Section 1866(j)(7) of the Social Security Act authorizes temporary enrollment moratoria where the Secretary determines they are necessary to prevent or combat fraud, waste, or abuse. Under the implementing regulation at 42 C.F.R. § 424.570, CMS may impose a six-month moratorium where it finds a significant potential for fraud, waste, or abuse. CMS may extend a moratorium in six-month increments. The original moratorium took effect May 13, 2026, and was announced May 15, 2026. CMS states the conditions that justified the original moratorium have not abated. CMS points to recent California criminal cases, including an August 2026 guilty plea involving more than $2.2 million in fraudulent hospice claims and a March 2026 prison sentence of thirty-five months for defrauding Medicare of more than $14 million through hospice and diagnostic testing claims. CMS also cites a June 3, 2026 FBI public service announcement warning of emerging hospice fraud schemes. CMS consulted the HHS Office of Inspector General, which agreed that a significant potential for fraud, waste, or abuse remains.
The extension is narrower than the original moratorium. It covers only hospices enrolling for the first time, including those enrolling through a non-exempt change in majority ownership. The bar on currently enrolled hospices adding new practice locations ended on November 12, 2026, primarily because CMS is more concerned at present about new hospices, with which it may have no experience, than about enrolled hospices seeking to add a location, although CMS says the latter remain a concern. States still decide whether some form of hospice moratorium is appropriate for their Medicaid and CHIP programs, and the existing moratoria in Louisiana, Nevada, Ohio, Pennsylvania, and Rhode Island are not affected by this notice. CMS reports no evidence that the moratorium has materially reduced access to care, but it will keep monitoring, especially in rural areas. CMS considered letting the moratorium expire or limiting it to southern California and rejected both because CMS views the problem as nationwide.
The full text of the notice is available here.
Reporter, Kasey Ashford, Washington, D.C., +1 202-626-2906, kashford@kslaw.com
CMS Extends Moratorium on New Medicare Enrollments for Home Health Agencies But Permits Existing Home Health Agencies to Add Additional Locations
Effective November 12, 2026, CMS extended the nationwide temporary moratorium on Medicare enrollment of new home health agencies (HHAs) for another six months. CMS, however, narrowed the moratorium’s scope—it now applies only to initially enrolling HHAs, including HHAs that must initially enroll following a non-exempt change in majority ownership (CIMO), and no longer prevents currently enrolled HHAs from adding new locations.
Background on the Home Health Agency Temporary Moratorium
As King & Spalding previously reported, CMS imposed a six-month nationwide moratorium effective May 13, 2026, under which no new HHAs or HHA branches or practice locations could enroll in Medicare on or after the effective date. In connection with the moratorium announcement, CMS emphasized its broader enforcement posture toward existing providers and cited longstanding HHA program integrity concerns.
Summary of the Moratorium Extension
- Updated Justification: In justifying the extension, CMS cited recent home health prosecutions and settlements, an August 13, 2026, DOJ memorandum emphasizing home health enforcement, and its consultation with HHS-OIG, which agreed that significant potential for fraud, waste, and abuse remains. CMS also noted that it has seen no evidence that the moratorium materially reduced Medicare beneficiary access to HHA services nationally or in any state, that states have not reported Medicaid or CHIP access problems, and that it would continue monitoring access issues, particularly in rural areas.
- Continued Prohibition on Enrollments by New HHAs: The extension continues to apply to initially enrolling HHAs, both those enrolling for the first time and those enrolling pursuant to a non-exempt CIMO under 42 C.F.R. § 424.550(b), which generally applies to a CIMO within thirty-six months of the HHA’s initial enrollment or most recent CIMO.
- New Locations for Existing HHAs Permitted: The moratorium extension does not apply to additions of HHA branches, i.e., new locations. CMS explained that it is presently more concerned about new HHAs than about enrolled HHAs seeking to add a branch, though the latter remain “of concern.”
- State Moratoria Unaffected: CMS again left Medicaid and CHIP moratoria to the states. The CMS extension does not affect any moratoria that states implemented in response to CMS’s May moratorium.
The Federal Register notice extending the home health moratorium can be found here.
Reporter, Christopher C. Jew, Los Angeles, CA, +1 213 443 4336, cjew@kslaw.com
CLIENT ALERT
Offering the Carrot Before the Stick: Inside DOJ and HHS’s New Healthcare Self-Disclosure Pilot Program
For most of 2026, the federal government has sharpened the stick in its campaign against fraud, waste, and abuse, prioritizing healthcare fraud, by creating the new National Fraud Enforcement Division, increasing artificial intelligence-driven data analytics and reaching out affirmatively to data miners, accelerating review of qui tam cases, and creating an incentive program with the potential for upfront cash rewards for whistleblowers. On October 22, 2026, it offered a carrot to healthcare companies in contrast to its recent aggressive enforcement moves. The Department of Justice (“DOJ”) Civil Division and the Department of Health and Human Services (“HHS”) launched the Healthcare False Claims Act Self-Disclosure Pilot Program (“FCA SDPP” or “Pilot Program”), a six-month initiative that creates what the government touts as a clear and predictable pathway to resolve potential False Claims Act (“FCA”) violations. Healthcare companies that self-disclose can obtain a coordinated resolution of civil liability under the FCA and certain HHS administrative authorities in exchange for repaying 1.25 to 1.6 times the amount at issue, a significant discount from the treble damages and per-claim penalties available in a litigated FCA action or the typically double damages multiplier in settled actions. Read the full Client Alert here.
Editors: Chris Kenny and Ahsin Azim
Issue Editors: Alana Broe and Olivia Haimerl
The Best and Latest Insights
All in One Place.